233 related articles for article (PubMed ID: 22659593)
21. Contrast-enhanced US quantitatively detects changes of tumor perfusion in a murine breast cancer model during adriamycin chemotherapy.
Wang JW; Cao LH; Han F; Zheng W; Chen Y; Li AH; Zhou JH
Acta Radiol; 2013 Oct; 54(8):882-8. PubMed ID: 23761553
[TBL] [Abstract][Full Text] [Related]
22. Early antiangiogenic activity of SU11248 evaluated in vivo by dynamic contrast-enhanced magnetic resonance imaging in an experimental model of colon carcinoma.
Marzola P; Degrassi A; Calderan L; Farace P; Nicolato E; Crescimanno C; Sandri M; Giusti A; Pesenti E; Terron A; Sbarbati A; Osculati F
Clin Cancer Res; 2005 Aug; 11(16):5827-32. PubMed ID: 16115922
[TBL] [Abstract][Full Text] [Related]
23. Intra-Animal Comparison between Three-dimensional Molecularly Targeted US and Three-dimensional Dynamic Contrast-enhanced US for Early Antiangiogenic Treatment Assessment in Colon Cancer.
Wang H; Lutz AM; Hristov D; Tian L; Willmann JK
Radiology; 2017 Feb; 282(2):443-452. PubMed ID: 27490690
[TBL] [Abstract][Full Text] [Related]
24. Cluster analysis of quantitative parametric maps from DCE-MRI: application in evaluating heterogeneity of tumor response to antiangiogenic treatment.
Longo DL; Dastrù W; Consolino L; Espak M; Arigoni M; Cavallo F; Aime S
Magn Reson Imaging; 2015 Jul; 33(6):725-36. PubMed ID: 25839393
[TBL] [Abstract][Full Text] [Related]
25. Bisphosphonate risedronate reduces metastatic human breast cancer burden in bone in nude mice.
Sasaki A; Boyce BF; Story B; Wright KR; Chapman M; Boyce R; Mundy GR; Yoneda T
Cancer Res; 1995 Aug; 55(16):3551-7. PubMed ID: 7627963
[TBL] [Abstract][Full Text] [Related]
26. Contrast-Enhanced Ultrasound with VEGFR2-Targeted Microbubbles for Monitoring Regorafenib Therapy Effects in Experimental Colorectal Adenocarcinomas in Rats with DCE-MRI and Immunohistochemical Validation.
Eschbach RS; Clevert DA; Hirner-Eppeneder H; Ingrisch M; Moser M; Schuster J; Tadros D; Schneider M; Kazmierczak PM; Reiser M; Cyran CC
PLoS One; 2017; 12(1):e0169323. PubMed ID: 28060884
[TBL] [Abstract][Full Text] [Related]
27. Tumor microvascular changes in antiangiogenic treatment: assessment by magnetic resonance contrast media of different molecular weights.
Turetschek K; Preda A; Novikov V; Brasch RC; Weinmann HJ; Wunderbaldinger P; Roberts TP
J Magn Reson Imaging; 2004 Jul; 20(1):138-44. PubMed ID: 15221819
[TBL] [Abstract][Full Text] [Related]
28. [Baseline and contrast-enhanced ultrasound of the liver in tumor patients].
Oldenburg A; Albrecht T
Ultraschall Med; 2008 Oct; 29(5):488-98. PubMed ID: 19241505
[TBL] [Abstract][Full Text] [Related]
29. Ultrasound Molecular Imaging With BR55, a Predictive Tool of Antiangiogenic Treatment Efficacy in a Chemo-Induced Mammary Tumor Model.
Helbert A; Von Wronski M; Colevret D; Botteron C; Padilla F; Bettinger T; Tardy I; Hyvelin JM
Invest Radiol; 2020 Oct; 55(10):657-665. PubMed ID: 32229739
[TBL] [Abstract][Full Text] [Related]
30. VEGFR2-Targeted Contrast-Enhanced Ultrasound to Distinguish between Two Anti-Angiogenic Treatments.
Payen T; Dizeux A; Baldini C; Le Guillou-Buffello D; Lamuraglia M; Comperat E; Lucidarme O; Bridal SL
Ultrasound Med Biol; 2015 Aug; 41(8):2202-11. PubMed ID: 25980323
[TBL] [Abstract][Full Text] [Related]
31. Quantitative assessment of tumor blood flow in mice after treatment with different doses of an antiangiogenic agent with contrast-enhanced destruction-replenishment US.
Zhou JH; Cao LH; Liu JB; Zheng W; Liu M; Luo RZ; Han F; Li AH
Radiology; 2011 May; 259(2):406-13. PubMed ID: 21292869
[TBL] [Abstract][Full Text] [Related]
32. αvß3-Integrin-Targeted Magnetic Resonance Imaging for the Assessment of Early Antiangiogenic Therapy Effects in Orthotopic Breast Cancer Xenografts.
Kazmierczak PM; Schneider M; Habereder T; Hirner-Eppeneder H; Eschbach RS; Moser M; Reiser MF; Lauber K; Nikolaou K; Cyran CC
Invest Radiol; 2016 Nov; 51(11):746-755. PubMed ID: 27082316
[TBL] [Abstract][Full Text] [Related]
33. Advanced hepatocellular carcinoma: early evaluation of response to bevacizumab therapy at dynamic contrast-enhanced US with quantification--preliminary results.
Lassau N; Koscielny S; Chami L; Chebil M; Benatsou B; Roche A; Ducreux M; Malka D; Boige V
Radiology; 2011 Jan; 258(1):291-300. PubMed ID: 20980447
[TBL] [Abstract][Full Text] [Related]
34. Evaluation of treatment response of cilengitide in an experimental model of breast cancer bone metastasis using dynamic PET with 18F-FDG.
Cheng C; Komljenovic D; Pan L; Dimitrakopoulou-Strauss A; Strauss L; Bäuerle T
Hell J Nucl Med; 2011; 14(1):15-20. PubMed ID: 21512659
[TBL] [Abstract][Full Text] [Related]
35. Inflammatory breast cancer: dynamic contrast-enhanced MR in patients receiving bevacizumab--initial experience.
Thukral A; Thomasson DM; Chow CK; Eulate R; Wedam SB; Gupta SN; Wise BJ; Steinberg SM; Liewehr DJ; Choyke PL; Swain SM
Radiology; 2007 Sep; 244(3):727-35. PubMed ID: 17709827
[TBL] [Abstract][Full Text] [Related]
36. A rapid histological score for the semiquantitative assessment of bone metastases in experimental models of breast cancer.
Neudert M; Fischer C; Krempien B; Seibel MJ; Bauss F
Onkologie; 2008 Oct; 31(10):521-7. PubMed ID: 18854651
[TBL] [Abstract][Full Text] [Related]
37. Use of Quantitative Dynamic Contrast-Enhanced Ultrasound to Assess Response to Antiangiogenic Therapy in Children and Adolescents With Solid Malignancies: A Pilot Study.
McCarville MB; Coleman JL; Guo J; Li Y; Li X; Honnoll PJ; Davidoff AM; Navid F
AJR Am J Roentgenol; 2016 May; 206(5):933-9. PubMed ID: 26999488
[TBL] [Abstract][Full Text] [Related]
38. E-cadherin expression in human breast cancer cells suppresses the development of osteolytic bone metastases in an experimental metastasis model.
Mbalaviele G; Dunstan CR; Sasaki A; Williams PJ; Mundy GR; Yoneda T
Cancer Res; 1996 Sep; 56(17):4063-70. PubMed ID: 8752180
[TBL] [Abstract][Full Text] [Related]
39. Dynamic gadobutrol-enhanced MRI predicts early response to antivascular but not to antiproliferation therapy in a mouse xenograft model.
Dassler K; Scholle FD; Schütz G
Magn Reson Med; 2014 May; 71(5):1826-33. PubMed ID: 23754607
[TBL] [Abstract][Full Text] [Related]
40. Dose-response relationship in cisplatin-treated breast cancer xenografts monitored with dynamic contrast-enhanced ultrasound.
Chen Y; Han F; Cao LH; Li C; Wang JW; Li Q; Zheng W; Guo ZX; Li AH; Zhou JH
BMC Cancer; 2015 Mar; 15():136. PubMed ID: 25884471
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
